Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists
作者:Alexandre V. Ivachtchenko、Yan A. Ivanenkov、Oleg D. Mitkin、Anton A. Vorobiev、Irina V. Kuznetsova、Natalia A. Shevkun、Angela G. Koryakova、Ruben N. Karapetian、Andrey S. Trifelenkov、Dmitry V. Kravchenko、Mark S. Veselov、Nina V. Chufarova
DOI:10.1016/j.ejmech.2015.05.039
日期:2015.6
androgen receptor (AR) antagonists containing spiro-4-(5-oxo-3-phenyl-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile core was designed based on the SAR studies available from the reported AR antagonists and in silico modeling. Within the series, compound (R)-6 (ONC1–13B) and its related analogues, including its active N-dealkylated metabolite, were found to be the most potent molecules
基于可用的SAR研究,设计了一系列新型的高活性雄激素受体(AR)拮抗剂,它们包含螺-4-(5-氧代-3-苯基-2-硫代氧咪唑啉-1-基)-2-(三氟甲基)苄腈核心来自报道的AR拮抗剂和计算机模拟。在该系列中,发现化合物(R)-6(ONC1-13B)及其相关类似物,包括其活性的N-脱烷基代谢产物,是具有目标活性的最有效分子(IC 50,对雄激素敏感的人PCa LNCaP细胞)范围为59–80 nM(抑制PSA产生)。在所进行的测定中,所揭示的命中活性比比卡鲁胺,尼鲁米特和恩杂鲁米特活性高至少两倍。几种化合物被分类为部分激动剂。命中化合物在大鼠中显示出有益的药代动力学特征。对命中化合物进行了比较SAR和3D分子对接研究,阐明了观察到的结合力差异。